Scarica l'app Stockscreener
25.76
13.21%
-3.92
Dopo l'orario di chiusura:
26.13
0.37
+1.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart.com
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC (NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
Nektar (NKTR) Trading Paused Ahead of Important Announcement | N - GuruFocus
Nektar Therapeutics Increases Authorized Shares To 390 Million - MarketScreener
Nektar Therapeutics Approves Reverse Stock Split - TipRanks
Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com
BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World
What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st
Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World
GSK’s liver asset play grows group of $1B upfront deals - biocentury.com
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance
Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target By Investing.com - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World
Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World
Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com
Nektar: Q1 Earnings Snapshot - The Washington Post
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):